{"database": "open_comments", "table": "documents", "is_view": false, "human_description_en": "where agency_id = \"FDA\" sorted by comment_end_date descending", "rows": [["FDA-2026-N-0131-0001", "FDA", "FDA-2026-N-0131", "FDA Rare Disease Innovation Hub Future Programming; Request for Comments", "Notice", "Request for Comments", "2026-01-30", 2026, 1, "2026-01-30", "2027-01-01", "2026-03-22 09:00:09", "2026-01903", 1, 0, "09000064b91893ee"], ["FDA-2016-D-1280-0005", "FDA", "FDA-2016-D-1280", "Electronic Submission of Postmarketing Individual Case Safety Reports to the Food and Drug Administration Adverse Event Monitoring System Using International\nCouncil of Harmonisation E2B(R3) Data Standards; Regional Data Elements and Implementation Schedule", "Notice", "Announcement", "2026-04-06", 2026, 4, "2026-04-06", "2026-10-02", "2026-04-07 09:00:25", "2026-06660", 1, 0, "09000064b9253dbc"], ["FDA-2025-E-2426-0006", "FDA", "FDA-2025-E-2426", "Determination of Regulatory Review Period for Purposes of Patent Extension; BLUJEPA", "Notice", "Determinations", "2026-02-13", 2026, 2, "2026-02-13", "2026-08-13", "2026-02-13 20:03:13", "2026-02901", 1, 0, "09000064b91aa6fb"], ["FDA-2025-E-0152-0006", "FDA", "FDA-2025-E-0152", "Determination of Regulatory Review Period for Purposes of Patent Extension; COBENFY", "Notice", "Determinations", "2026-02-06", 2026, 2, "2026-02-06", "2026-08-06", "2026-02-06 20:05:43", "2026-02388", 1, 0, "09000064b919467e"], ["FDA-2025-E-0153-0006", "FDA", "FDA-2025-E-0153", "Determination of Regulatory Review Period for Purposes of Patent Extension; COBENFY", "Notice", "Determinations", "2026-02-06", 2026, 2, "2026-02-06", "2026-08-06", "2026-02-06 20:06:34", "2026-02388", 1, 0, "09000064b919467f"], ["FDA-2024-E-3539-0006", "FDA", "FDA-2024-E-3539", "Determination of Regulatory Review Period for Purposes of Patent Extension; BEQVEZ", "Notice", "Determinations", "2026-02-06", 2026, 2, "2026-02-06", "2026-08-06", "2026-02-14 13:19:52", "2026-02387", 1, 0, "09000064b9195b4d"], ["FDA-2025-E-0154-0006", "FDA", "FDA-2025-E-0154", "Determination of Regulatory Review Period for Purposes of Patent Extension; COBENFY", "Notice", "Determinations", "2026-02-06", 2026, 2, "2026-02-06", "2026-08-06", "2026-02-06 20:07:01", "2026-02388", 1, 0, "09000064b9195c17"], ["FDA-2026-N-3273-0001", "FDA", "FDA-2026-N-3273", "Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments; Public Meeting; Request for Comments", "Notice", "Request for Comments", "2026-04-15", 2026, 4, "2026-04-15", "2026-07-24", "2026-04-15 17:05:22", "2026-07248", 1, 0, "09000064b9282224"], ["FDA-2026-P-0749-0001", "FDA", "FDA-2026-P-0749", "Citizen Petition from Apotex Inc.", "Other", "Citizen Petition", "2026-01-26", 2026, 1, "2026-01-26", "2026-07-23", "2026-01-27 01:08:18", null, 1, 0, "09000064b9182c73"], ["FDA-2026-D-1255-0002", "FDA", "FDA-2026-D-1255", "Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Draft Guidance for Industry", "Other", "Guidance", "2026-04-15", 2026, 4, "2026-04-15", "2026-07-15", "2026-04-16 09:00:16", null, 1, 0, "09000064b9282a2a"], ["FDA-2023-N-0119-0020", "FDA", "FDA-2023-N-0119", "Fiscal Year 2026 Generic Drug Science and Research Initiatives Workshop; Public Workshop; Request for\nComments", "Notice", "Request for Comments", "2026-02-27", 2026, 2, "2026-02-27", "2026-07-11", "2026-04-14 09:00:18", "2026-03961", 1, 0, "09000064b91e326c"], ["FDA-2026-N-2366-0001", "FDA", "FDA-2026-N-2366", "Commissioner\u2019s National Priority Voucher (CNPV) Pilot Program; Public Hearing; Request for Comments", "Notice", "Request for Comments", "2026-03-23", 2026, 3, "2026-03-23", "2026-06-30", "2026-04-12 09:00:14", "2026-05573", 1, 0, "09000064b922c21a"], ["FDA-2026-N-2742-0001", "FDA", "FDA-2026-N-2742", "Agency Information Collection Activities; Proposed Collection; Comment Request; Color Additive Certification", "Notice", "60 Day Proposed Information Collection", "2026-04-10", 2026, 4, "2026-04-10", "2026-06-10", "2026-04-10 18:01:37", "2026-06936", 1, 0, "09000064b926825a"], ["FDA-2026-N-2743-0001", "FDA", "FDA-2026-N-2743", "Agency Information Collection Activities; Proposed Collection; Comment Request; Submission of Petitions: Food Additive, Color Additive (Including Labeling), Submission of Information to a Master File in Support of Petitions; and Electronic Submission Using Food and Drug Administration Form 3503", "Notice", "60 Day Proposed Information Collection", "2026-04-10", 2026, 4, "2026-04-10", "2026-06-10", "2026-04-10 18:22:24", "2026-06935", 1, 0, "09000064b926821b"], ["FDA-2026-N-2915-0001", "FDA", "FDA-2026-N-2915", "Agency Information Collection Activities; Proposed Collection; Comment Request; Premarket Approval of Medical Devices", "Notice", "60 Day Proposed Information Collection", "2026-04-10", 2026, 4, "2026-04-10", "2026-06-10", "2026-04-10 17:47:50", "2026-06906", 1, 0, "09000064b9268328"], ["FDA-2026-N-2431-0001", "FDA", "FDA-2026-N-2431", "Agency Information Collection Activities; Proposed Collection; Comment Request; Administrative Practices and Procedures; Formal Hearings", "Notice", "60 Day Proposed Information Collection", "2026-04-07", 2026, 4, "2026-04-07", "2026-06-09", "2026-04-14 19:40:33", "2026-06719", 1, 0, "09000064b9255485"], ["FDA-2025-E-0863-0006", "FDA", "FDA-2025-E-0863", "Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY", "Notice", "Determinations", "2026-04-03", 2026, 4, "2026-04-03", "2026-06-03", "2026-04-03 17:37:03", "2026-06478", 1, 0, "09000064b924cccb"], ["FDA-2025-E-0845-0006", "FDA", "FDA-2025-E-0845", "Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY", "Notice", "Determinations", "2026-04-03", 2026, 4, "2026-04-03", "2026-06-03", "2026-04-03 17:34:01", "2026-06478", 1, 0, "09000064b924dac3"], ["FDA-2025-E-0866-0006", "FDA", "FDA-2025-E-0866", "Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY", "Notice", "Determinations", "2026-04-03", 2026, 4, "2026-04-03", "2026-06-03", "2026-04-03 17:42:13", "2026-06478", 1, 0, "09000064b924ccce"], ["FDA-2025-E-0372-0005", "FDA", "FDA-2025-E-0372", "Determination of Regulatory Review Period for Purposes of Patent Extension; ZIIHERA", "Notice", "Determinations", "2026-04-03", 2026, 4, "2026-04-03", "2026-06-03", "2026-04-03 17:52:42", "2026-06476", 1, 0, "09000064b924da88"], ["FDA-2025-E-3074-0006", "FDA", "FDA-2025-E-3074", "Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS", "Notice", "Determinations", "2026-04-03", 2026, 4, "2026-04-03", "2026-06-03", "2026-04-03 17:57:30", "2026-06480", 1, 0, "09000064b924c470"], ["FDA-2025-E-0871-0006", "FDA", "FDA-2025-E-0871", "Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY", "Notice", "Determinations", "2026-04-03", 2026, 4, "2026-04-03", "2026-06-03", "2026-04-03 17:49:10", "2026-06478", 1, 0, "09000064b924c46e"], ["FDA-2025-E-3073-0006", "FDA", "FDA-2025-E-3073", "Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS", "Notice", "Determinations", "2026-04-03", 2026, 4, "2026-04-03", "2026-06-03", "2026-04-03 17:55:54", "2026-06480", 1, 0, "09000064b924da86"], ["FDA-2025-E-3626-0006", "FDA", "FDA-2025-E-3626", "Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA", "Notice", "Determinations", "2026-04-03", 2026, 4, "2026-04-03", "2026-06-03", "2026-04-03 17:59:57", "2026-06479", 1, 0, "09000064b924d98d"], ["FDA-2025-E-0870-0006", "FDA", "FDA-2025-E-0870", "Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY", "Notice", "Determinations", "2026-04-03", 2026, 4, "2026-04-03", "2026-06-03", "2026-04-03 17:48:07", "2026-06478", 1, 0, "09000064b924c46d"], ["FDA-2026-N-2740-0001", "FDA", "FDA-2026-N-2740", "Agency Information Collection Activities; Proposed Collection; Comment Request; Customer/Partner Customer Service Satisfaction Surveys", "Notice", "60 Day Proposed Information Collection", "2026-04-03", 2026, 4, "2026-04-03", "2026-06-03", "2026-04-03 17:29:44", "2026-06482", 1, 0, "09000064b924dac4"], ["FDA-2025-E-0868-0006", "FDA", "FDA-2025-E-0868", "Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY", "Notice", "Determinations", "2026-04-03", 2026, 4, "2026-04-03", "2026-06-03", "2026-04-03 17:44:23", "2026-06478", 1, 0, "09000064b924c0e1"], ["FDA-2025-E-0865-0006", "FDA", "FDA-2025-E-0865", "Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY", "Notice", "Determinations", "2026-04-03", 2026, 4, "2026-04-03", "2026-06-03", "2026-04-03 17:39:45", "2026-06478", 1, 0, "09000064b924cccd"], ["FDA-2025-E-1672-0007", "FDA", "FDA-2025-E-1672", "Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO", "Notice", "Determinations", "2026-04-03", 2026, 4, "2026-04-03", "2026-06-03", "2026-04-03 18:06:28", "2026-06477", 1, 0, "09000064b924d940"], ["FDA-2014-E-2328-0006", "FDA", "FDA-2014-E-2328", "Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER", "Notice", "Determinations", "2026-04-03", 2026, 4, "2026-04-03", "2026-06-03", "2026-04-03 18:09:13", "2026-06483", 1, 0, "09000064b924d4f5"], ["FDA-2025-E-0864-0006", "FDA", "FDA-2025-E-0864", "Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY", "Notice", "Determinations", "2026-04-03", 2026, 4, "2026-04-03", "2026-06-03", "2026-04-03 17:38:27", "2026-06478", 1, 0, "09000064b924cccc"], ["FDA-2025-E-0872-0006", "FDA", "FDA-2025-E-0872", "Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY", "Notice", "Determinations", "2026-04-03", 2026, 4, "2026-04-03", "2026-06-03", "2026-04-03 17:50:02", "2026-06478", 1, 0, "09000064b924c46f"], ["FDA-2025-E-0867-0006", "FDA", "FDA-2025-E-0867", "Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY", "Notice", "Determinations", "2026-04-03", 2026, 4, "2026-04-03", "2026-06-03", "2026-04-03 17:43:31", "2026-06478", 1, 0, "09000064b924c0e0"], ["FDA-2025-E-0158-0006", "FDA", "FDA-2025-E-0158", "Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI", "Notice", "Determinations", "2026-04-03", 2026, 4, "2026-04-03", "2026-06-03", "2026-04-03 18:04:00", "2026-06481", 1, 0, "09000064b924d942"], ["FDA-2025-E-0869-0006", "FDA", "FDA-2025-E-0869", "Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY", "Notice", "Determinations", "2026-04-03", 2026, 4, "2026-04-03", "2026-06-03", "2026-04-03 17:45:32", "2026-06478", 1, 0, "09000064b924ba07"], ["FDA-2026-C-3071-0001", "FDA", "FDA-2026-C-3071", "Filing of Color Additive Petition: International Association of Color Manufacturers; Request to Amend the Color Additive Regulations to Remove the Solvents Methylene Chloride, Trichloroethylene, and Ethylene Dichloride", "Proposed Rule", "Petition", "2026-04-01", 2026, 4, "2026-04-01", "2026-06-02", "2026-04-01 17:16:12", "2026-06295", 1, 0, "09000064b9249960"], ["FDA-2026-N-0809-0001", "FDA", "FDA-2026-N-0809", "Recommendations on Scale-Up and Postapproval Changes Guidances for Industry; Request for Comments", "Notice", "Request for Comments", "2026-03-03", 2026, 3, "2026-03-03", "2026-06-02", "2026-04-13 09:00:28", "2026-04196", 1, 0, "09000064b91ed501"], ["FDA-2026-N-2476-0001", "FDA", "FDA-2026-N-2476", "Advancing the Use of Digital Health Technologies in Clinical Investigations for Drugs and Biological Products;\nRequest for Information and Comments", "Notice", "Request for Comments", "2026-03-31", 2026, 3, "2026-03-31", "2026-06-02", "2026-04-10 09:00:28", "2026-06184", 1, 0, "09000064b92439d6"], ["FDA-2026-N-2590-0001", "FDA", "FDA-2026-N-2590", "Microbiology Devices; Reclassification of Mycobacterium Tuberculosis Cell-Mediated Immunity Tests and Immune Response Enzyme-Linked Immunospot Tests", "Proposed Rule", "Request for Comment", "2026-03-30", 2026, 3, "2026-03-30", "2026-05-30", "2026-04-13 09:00:30", "2026-06064", 1, 0, "09000064b92437b6"], ["FDA-2024-E-5140-0006", "FDA", "FDA-2024-E-5140", "Determination of Regulatory Review Period for Purposes of Patent Extension; ENVISION MAMMOGRAPHY PLATFORM", "Notice", "Determinations", "2025-11-24", 2025, 11, "2025-11-24", "2026-05-27", "2026-01-24 13:16:48", "2025-20667", 1, 0, "09000064b908e3f0"], ["FDA-2024-E-5139-0006", "FDA", "FDA-2024-E-5139", "Determination of Regulatory Review Period for Purposes of Patent Extension; ENVISION MAMMOGRAPHY PLATFORM", "Notice", "Determinations", "2025-11-24", 2025, 11, "2025-11-24", "2026-05-27", "2026-01-24 13:16:48", "2025-20667", 1, 0, "09000064b908e3ef"], ["FDA-2024-E-5141-0006", "FDA", "FDA-2024-E-5141", "Determination of Regulatory Review Period for Purposes of Patent Extension; ENVISION MAMMOGRAPHY PLATFORM", "Notice", "Determinations", "2025-11-24", 2025, 11, "2025-11-24", "2026-05-27", "2026-01-24 13:16:50", "2025-20667", 1, 0, "09000064b9092f99"], ["FDA-2024-E-5681-0006", "FDA", "FDA-2024-E-5681", "Determination of Regulatory Review Period for Purposes of Patent Extension; ALTIUS DIRECT ELECTRICAL NERVE STIMULATION\nSYSTEM", "Notice", "Determinations", "2025-11-24", 2025, 11, "2025-11-24", "2026-05-27", "2025-11-24 19:32:14", "2025-20668", 1, 0, "09000064b9093521"], ["FDA-2026-N-2365-0001", "FDA", "FDA-2026-N-2365", "Agency Information Collection Activities; Proposed Collection; Comment Request; Reporting Associated With Animal Drug and Animal Generic Drug User Fees", "Notice", "60 Day Proposed Information Collection", "2026-03-23", 2026, 3, "2026-03-23", "2026-05-23", "2026-03-23 17:37:47", "2026-05620", 1, 0, "09000064b922c25e"], ["FDA-2026-N-2364-0001", "FDA", "FDA-2026-N-2364", "Agency Information Collection Activities; Proposed Collection; Comment Request; Food and Drug\nAdministration Advisory Committees", "Notice", "60 Day Proposed Information Collection", "2026-03-23", 2026, 3, "2026-03-23", "2026-05-23", "2026-03-25 09:00:29", "2026-05623", 1, 0, "09000064b922c187"], ["FDA-2025-D-2837-0002", "FDA", "FDA-2025-D-2837", "Questions and Answers About Requirements for Additional Traceability Records for Certain Foods: Guidance for Industry - Draft Guidance", "Other", "Guidance", "2026-02-20", 2026, 2, "2026-02-20", "2026-05-22", "2026-02-20 20:47:16", null, 1, 0, "09000064b91c9d9a"], ["FDA-2026-N-1304-0001", "FDA", "FDA-2026-N-1304", "Agenda for the U.S. Food and Drug Administration (FDA) Virtual Public Meeting Food Allergen Thresholds and Their Potential Applications 2-18-2026", "Other", "Agenda", "2026-02-18", 2026, 2, "2026-02-18", "2026-05-20", "2026-04-10 09:00:23", null, 1, 0, "09000064b91b5eeb"], ["FDA-2025-N-5996-0001", "FDA", "FDA-2025-N-5996", "Medical Devices; Radiology Devices; Classification of Blood Irradiators", "Proposed Rule", "Notice of Proposed Rulemaking (NPRM)", "2026-03-18", 2026, 3, "2026-03-18", "2026-05-19", "2026-03-29 09:00:14", "2026-05320", 1, 0, "09000064b92216a5"], ["FDA-2025-N-5995-0001", "FDA", "FDA-2025-N-5995", "Effective Date of Requirement for Premarket Approval Applications for Blood Irradiators Intended To Prevent Metastasis", "Proposed Rule", "Notice of Proposed Rulemaking (NPRM)", "2026-03-18", 2026, 3, "2026-03-18", "2026-05-19", "2026-03-21 09:00:16", "2026-05322", 1, 0, "09000064b92215cb"], ["FDA-2026-N-1849-0001", "FDA", "FDA-2026-N-1849", "Agency Information Collection Activities; Proposed Collection; Comment Request; Premarket Notifications Submission", "Notice", "60 Day Proposed Information Collection", "2026-03-19", 2026, 3, "2026-03-19", "2026-05-19", "2026-03-19 17:24:48", "2026-05329", 1, 0, "09000064b9224334"], ["FDA-2026-N-2279-0001", "FDA", "FDA-2026-N-2279", "Preparation for International Cooperation on Cosmetics Regulation Twentieth Annual Meeting (ICCR\u201320); Request for Comments", "Notice", "Request for Comments", "2026-03-18", 2026, 3, "2026-03-18", "2026-05-19", "2026-04-03 09:00:22", "2026-05280", 1, 0, "09000064b922165c"], ["FDA-2025-D-6131-0002", "FDA", "FDA-2025-D-6131", "General Considerations for the Use of New Approach Methodologies in Drug Development; Guidance for Industry - Draft Guidance", "Other", "Guidance", "2026-03-19", 2026, 3, "2026-03-19", "2026-05-19", "2026-04-15 09:00:24", null, 1, 0, "09000064b9223609"], ["FDA-2026-N-1736-0001", "FDA", "FDA-2026-N-1736", "Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements", "Notice", "60 Day Proposed Information Collection", "2026-03-13", 2026, 3, "2026-03-13", "2026-05-13", "2026-03-13 17:05:05", "2026-04938", 1, 0, "09000064b92145ad"], ["FDA-2026-D-1817-0002", "FDA", "FDA-2026-D-1817", "Flavored Electronic Nicotine Delivery Systems (ENDS) Premarket Applications\u2014Considerations Related to Youth Risk - Draft Guidance for Industry", "Other", "Guidance", "2026-03-11", 2026, 3, "2026-03-11", "2026-05-12", "2026-04-14 09:00:19", null, 1, 0, "09000064b920c96d"], ["FDA-2011-D-0611-0094", "FDA", "FDA-2011-D-0611", "New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4) Guidance for Industry - \nDraft Guidance", "Other", "Guidance", "2026-03-10", 2026, 3, "2026-03-10", "2026-05-12", "2026-03-14 09:00:14", null, 1, 0, "09000064b92071bb"], ["FDA-2025-N-4731-0052", "FDA", "FDA-2025-N-4731", "Increasing Access to Nonprescription Drugs; Public Meeting; Request for Comments", "Notice", "Request for Comments", "2026-04-15", 2026, 4, "2026-04-15", "2026-05-09", "2026-04-15 17:08:45", "2026-07335", 1, 0, "09000064b9282192"], ["FDA-2025-D-1504-0002", "FDA", "FDA-2025-D-1504", "Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection: Draft Guidance for Industry", "Other", "Guidance", "2026-03-09", 2026, 3, "2026-03-09", "2026-05-09", "2026-04-10 09:00:26", null, 1, 0, "09000064b9200f6d"], ["FDA-2025-E-0493-0006", "FDA", "FDA-2025-E-0493", "Determination of Regulatory Review Period for Purposes of Patent Extension; ENSACOVE", "Notice", "Determinations", "2026-03-06", 2026, 3, "2026-03-06", "2026-05-06", "2026-03-06 19:06:30", "2026-04491", 1, 0, "09000064b91f8458"], ["FDA-2024-D-4388-0002", "FDA", "FDA-2024-D-4388", "New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers Guidance for Industry - Draft Guidance", "Other", "Guidance", "2026-03-04", 2026, 3, "2026-03-04", "2026-05-05", "2026-03-09 09:00:19", null, 1, 0, "09000064b91ef6ec"], ["FDA-2026-N-2741-0001", "FDA", "FDA-2026-N-2741", "Consideration of Acceptable Market Name Change for Certain Rockfish (Sebastes spp.); Request for Information", "Notice", "Requests for Information (RFI)", "2026-04-01", 2026, 4, "2026-04-01", "2026-05-02", "2026-04-14 19:40:35", "2026-06294", 1, 0, "09000064b924995a"], ["FDA-2026-N-1867-0001", "FDA", "FDA-2026-N-1867", "Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments\u2014New Drug Application 220359, for Camizestrant Tablets; Supplemental New Drug Application (sNDA) 218197/S\u2013004, for Truqap (Capivasertib) Tablets", "Notice", "Request for Comments", "2026-03-09", 2026, 3, "2026-03-09", "2026-04-30", "2026-04-16 09:00:12", "2026-04497", 1, 0, "09000064b9200842"], ["FDA-2007-D-0369-2444", "FDA", "FDA-2007-D-0369", "PSG_020151 - Draft Guidance on Venlafaxine Hydrochloride", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:22:37", null, 1, 0, "09000064b91df4e6"], ["FDA-2007-D-0369-2442", "FDA", "FDA-2007-D-0369", "PSG_020144 - Draft Guidance on Nitroglycerin", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:21:57", null, 1, 0, "09000064b91df4d8"], ["FDA-2007-D-0369-2432", "FDA", "FDA-2007-D-0369", "PSG_018084 - Draft Guidance on Tolmetin Sodium", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:18:51", null, 1, 0, "09000064b91df465"], ["FDA-2007-D-0369-2457", "FDA", "FDA-2007-D-0369", "PSG_021336 - Draft Guidance on Selegiline", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:26:39", null, 1, 0, "09000064b91e011b"], ["FDA-2007-D-0369-2440", "FDA", "FDA-2007-D-0369", "PSG_019982 - Draft Guidance on Bisoprolol Fumarate", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:21:21", null, 1, 0, "09000064b91df4d4"], ["FDA-2007-D-0369-2447", "FDA", "FDA-2007-D-0369", "PSG_020375 - Draft Guidance on Estradiol", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:23:38", null, 1, 0, "09000064b91df4f2"], ["FDA-2007-D-0369-2438", "FDA", "FDA-2007-D-0369", "PSG_019813 - Draft Guidance on Fentanyl", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:20:47", null, 1, 0, "09000064b91df4d0"], ["FDA-2007-D-0369-2459", "FDA", "FDA-2007-D-0369", "PSG_021427 - Draft Guidance on Duloxetine Hydrochloride", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:27:37", null, 1, 0, "09000064b91e011f"], ["FDA-2007-D-0369-2461", "FDA", "FDA-2007-D-0369", "PSG_021514 - Draft Guidance on Methylphenidate", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:29:28", null, 1, 0, "09000064b91e0123"], ["FDA-2007-D-0369-2520", "FDA", "FDA-2007-D-0369", "PSG_218466 - Draft Guidance on Alpelisib", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:50:12", null, 1, 0, "09000064b91e01d3"], ["FDA-2007-D-0369-2511", "FDA", "FDA-2007-D-0369", "PSG_216352 - Draft Guidance on Paliperidone Palmitate", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:47:03", null, 1, 0, "09000064b91e01b4"], ["FDA-2007-D-0369-2512", "FDA", "FDA-2007-D-0369", "PSG_216665 - Draft Guidance on Diazoxide Choline", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:47:20", null, 1, 0, "09000064b91e01b6"], ["FDA-2007-D-0369-2508", "FDA", "FDA-2007-D-0369", "PSG_215431 - Draft Guidance on Meloxicam; Rizatriptan Benzoate", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:46:07", null, 1, 0, "09000064b91e01ad"], ["FDA-2007-D-0369-2475", "FDA", "FDA-2007-D-0369", "PSG_202211 - Draft Guidance on Oxybutynin", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:35:11", null, 1, 0, "09000064b91e0140"], ["FDA-2007-D-0369-2466", "FDA", "FDA-2007-D-0369", "PSG_022029 - Draft Guidance on Menthol; Methyl Salicylate", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:31:54", null, 1, 0, "09000064b91e012d"], ["FDA-2007-D-0369-2467", "FDA", "FDA-2007-D-0369", "PSG_022083 - Draft Guidance on Rivastigmine", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:32:28", null, 1, 0, "09000064b91e012f"], ["FDA-2007-D-0369-2464", "FDA", "FDA-2007-D-0369", "PSG_021829 - Draft Guidance on Rotigotine", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:30:54", null, 1, 0, "09000064b91e0129"], ["FDA-2007-D-0369-2497", "FDA", "FDA-2007-D-0369", "PSG_213224 - Draft Guidance on Octreotide acetate", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:42:17", null, 1, 0, "09000064b91e018a"], ["FDA-2007-D-0369-2490", "FDA", "FDA-2007-D-0369", "PSG_211843 - Draft Guidance on Tiopronin", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:39:55", null, 1, 0, "09000064b91e0172"], ["FDA-2007-D-0369-2481", "FDA", "FDA-2007-D-0369", "PSG_207620 - Draft Guidance on Sacubitril; Valsartan", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:37:17", null, 1, 0, "09000064b91e0156"], ["FDA-2007-D-0369-2489", "FDA", "FDA-2007-D-0369", "PSG_211733 - Draft Guidance on Acetaminophen; Ibuprofen", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:39:39", null, 1, 0, "09000064b91e0170"], ["FDA-2007-D-0369-2479", "FDA", "FDA-2007-D-0369", "PSG_206089 - Draft Guidance on Testosterone Undecanoate", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:36:31", null, 1, 0, "09000064b91e0152"], ["FDA-2007-D-0369-2469", "FDA", "FDA-2007-D-0369", "PSG_022264 - Draft Guidance on Paliperidone Palmitate", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:33:09", null, 1, 0, "09000064b91e0133"], ["FDA-2007-D-0369-2473", "FDA", "FDA-2007-D-0369", "PSG_085635 - Draft Guidance on Testosterone Cypionate", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:34:27", null, 1, 0, "09000064b91e013c"], ["FDA-2007-D-0369-2488", "FDA", "FDA-2007-D-0369", "PSG_210868 - Draft Guidance on Lorlatinib", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:39:21", null, 1, 0, "09000064b91e016e"], ["FDA-2007-D-0369-2486", "FDA", "FDA-2007-D-0369", "PSG_209310 - Draft Guidance on Mometasone Furoate", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:38:46", null, 1, 0, "09000064b91e016a"], ["FDA-2007-D-0369-2506", "FDA", "FDA-2007-D-0369", "PSG_215401 - Draft Guidance on Dextroamphetamine", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:45:23", null, 1, 0, "09000064b91e01a9"], ["FDA-2007-D-0369-2522", "FDA", "FDA-2007-D-0369", "PSG_218585 - Draft Guidance on Aceclidine Hydrochloride", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:51:02", null, 1, 0, "09000064b91e01d7"], ["FDA-2007-D-0369-2509", "FDA", "FDA-2007-D-0369", "PSG_215602 - Draft Guidance on Baclofen", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:46:21", null, 1, 0, "09000064b91e01af"], ["FDA-2007-D-0369-2516", "FDA", "FDA-2007-D-0369", "PSG_217225 - Draft Guidance on Avacincaptad Pegol Sodium", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:48:56", null, 1, 0, "09000064b91e01cb"], ["FDA-2007-D-0369-2507", "FDA", "FDA-2007-D-0369", "PSG_215429 - Draft Guidance on Venlafaxine Besylate", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:45:49", null, 1, 0, "09000064b91e01ab"], ["FDA-2007-D-0369-2443", "FDA", "FDA-2007-D-0369", "PSG_020145 - Draft Guidance on Nitroglycerin", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:22:16", null, 1, 0, "09000064b91df4da"], ["FDA-2007-D-0369-2460", "FDA", "FDA-2007-D-0369", "PSG_021447 - Draft Guidance on Tizanidine Hydrochloride", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:27:59", null, 1, 0, "09000064b91e0121"], ["FDA-2007-D-0369-2446", "FDA", "FDA-2007-D-0369", "PSG_020357 - Draft Guidance on Metformin Hydrochloride", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:23:14", null, 1, 0, "09000064b91df4f0"], ["FDA-2007-D-0369-2448", "FDA", "FDA-2007-D-0369", "PSG_020489 - Draft Guidance on Testosterone", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:23:57", null, 1, 0, "09000064b91df4f4"], ["FDA-2007-D-0369-2454", "FDA", "FDA-2007-D-0369", "PSG_021234 - Draft Guidance on Diclofenac Epolamine", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:25:35", null, 1, 0, "09000064b91e010a"], ["FDA-2007-D-0369-2500", "FDA", "FDA-2007-D-0369", "PSG_214410 - Draft Guidance on Baloxavir Marboxil", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:43:31", null, 1, 0, "09000064b91e0190"], ["FDA-2007-D-0369-2494", "FDA", "FDA-2007-D-0369", "PSG_212516 - Draft Guidance on Duloxetine Hydrochloride", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:41:20", null, 1, 0, "09000064b91e0184"], ["FDA-2007-D-0369-2484", "FDA", "FDA-2007-D-0369", "PSG_208143 - Draft Guidance on Barium Sulfate", "Other", "Guidance", "2026-02-27", 2026, 2, "2026-02-27", "2026-04-29", "2026-02-27 19:38:13", null, 1, 0, "09000064b91e015c"]], "truncated": false, "filtered_table_rows_count": 184, "expanded_columns": [], "expandable_columns": [], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"agency_id\" = :p0 order by comment_end_date desc limit 101", "params": {"p0": "FDA"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/open_comments/documents.json?agency_id=FDA", "results": [{"value": "FDA", "label": "FDA", "count": 184, "toggle_url": "https://regs.datadawn.org/open_comments/documents.json", "selected": true}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/open_comments/documents.json?agency_id=FDA", "results": [{"value": "Other", "label": "Other", "count": 110, "toggle_url": "https://regs.datadawn.org/open_comments/documents.json?agency_id=FDA&document_type=Other", "selected": false}, {"value": "Notice", "label": "Notice", "count": 70, "toggle_url": "https://regs.datadawn.org/open_comments/documents.json?agency_id=FDA&document_type=Notice", "selected": false}, {"value": "Proposed Rule", "label": "Proposed Rule", "count": 4, "toggle_url": "https://regs.datadawn.org/open_comments/documents.json?agency_id=FDA&document_type=Proposed+Rule", "selected": false}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://regs.datadawn.org/open_comments/documents.json?agency_id=FDA&_facet=subtype"}, {"name": "posted_year", "toggle_url": "https://regs.datadawn.org/open_comments/documents.json?agency_id=FDA&_facet=posted_year"}, {"name": "posted_month", "toggle_url": "https://regs.datadawn.org/open_comments/documents.json?agency_id=FDA&_facet=posted_month"}, {"name": "posted_date", "type": "date", "toggle_url": "https://regs.datadawn.org/open_comments/documents.json?agency_id=FDA&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://regs.datadawn.org/open_comments/documents.json?agency_id=FDA&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://regs.datadawn.org/open_comments/documents.json?agency_id=FDA&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://regs.datadawn.org/open_comments/documents.json?agency_id=FDA&_facet_date=last_modified"}], "next": "2026-04-29,FDA-2007-D-0369-2484", "next_url": "https://regs.datadawn.org/open_comments/documents.json?agency_id=FDA&_next=2026-04-29%2CFDA-2007-D-0369-2484&_sort_desc=comment_end_date", "private": false, "allow_execute_sql": true, "query_ms": 2212.9994882270694, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}